Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis-Reference-Cited by-同舟云学术

Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis

Published:2023-09 Issue:5 Volume:10 Page:
ISSN:2332-7812
Container-title:Neurology Neuroimmunology & Neuroinflammation
language:en
Short-container-title:Neurol Neuroimmunol Neuroinflamm

Author:

Claverie Roxane¹^ORCID,Perriguey Marine¹^ORCID,Rico Audrey¹^ORCID,Boutiere Clemence¹^ORCID,Demortiere Sarah¹^ORCID,Durozard Pierre¹^ORCID,Hilezian Frederic¹^ORCID,Dubrou Clea¹^ORCID,Vely Frederic¹^ORCID,Pelletier Jean¹,Audoin Bertrand¹^ORCID,Maarouf Adil¹^ORCID

Affiliation:

1. From the Department of Neurology (B.A., M.P., A.R., C.B., S.D., F.H., J.P., A.M.), CRMBM, University Hospital of Marseille, Aix-Marseille University; Service d'immunologie (D.C., F.V.), Marseille Immunopôle, APHM, Aix Marseille University, CNRS, INSERM, CIML; Faculté de Pharmacie (R.C.), Aix-Marseille University; and Centre hospitalier d'Ajaccio (P.D.), Service de Neurologie, France.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical),Neurology

Link

https://www.neurology.org/doi/pdfdirect/10.1212/NXI.0000000000200152

Reference43 articles.

1. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

2. Rituximab treatment results in impaired secondary humoral immune responsiveness

3. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab

4. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

5. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-CD20 therapies for pediatric-onset multiple sclerosis: A systematic review;Multiple Sclerosis and Related Disorders;2024-11

2. B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease;Current Neurology and Neuroscience Reports;2024-09-11

3. De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis;Current Neurology and Neuroscience Reports;2024-07-12

4. Hospital‐Treated Infections and Risk of Disability Worsening in Multiple Sclerosis;Annals of Neurology;2024-07-10

5. Safety and effectiveness of disease-modifying therapies after switching from natalizumab;Multiple Sclerosis Journal;2024-07